

Index

A

Acoustic separation, 52
Adventitious agents, 71, 167, 187, 253
Aeration, 73, 79, 215, 231
Aggregation, 126
Airlift, 78, 80
Alternative tangential flow (ATF), 89
Amidation, 141
Amino acids, 40, 43, 85, 123, 128, 144
 misincorporation, 125, 133
Animal-derived raw materials (ADRM), 248
Animal sourced materials (ASM), 167
Antibodies, monoclonal, 2, 69, 190
Antithrombin, 13
Artificial chromosome expression (ACE), 18
ASP/ASN hydroxylase, 151
Asparagine deamidation, 152
Aspartate, succinimide/isoaspartate, 152
Automation, 11, 24

B

Baby hamster kidney (BHK) cells, 5, 227, 229
Batch, 8, 35
 repeated, 39
Biologics, 2
Biomufacturing, 85, 123, 185, 217, 238
Biopharmaceuticals, 1, 2, 185
Bioprocess development, 11
Bioreactors, 69, 123
Bovine spongiform encephalopathy (BSE), 169
Bovine viral diarrhea virus (BVDV), 169
Bubble column, 78, 80

C

Cache Valley virus (CVV), 169
Capacity, 185

γ -Carboxylation, 151
Cell cultures, 35, 69, 123
 characterization, 93
 development, 93
 operations, 1
 scale-up, 93
 technology, 245
Cell discard rate (CDR), 53
Cell engineering, 11
Cell retention, 49
Cell-specific perfusion rate (CSPR), 52
Chemically defined media (CDM), 170
Chinese hamster ovary (CHO) cells, 5, 11,
 227, 253
ClonePixFL, 22
Continuous processing, 35, 55, 78
Contract manufacturing, 185, 192
Control point matrix (CPM), 95, 97
Control strategy, 93
Cre/Lox, 19
Cricetulus griseus, 229
CRISPR, 15
Critical quality attributes (CQAs), 93, 95,
 99, 250
Cross-species hybridization, 232
Cytochrome P450, 44
Cytopathic effects (CPE), 168

D

Data analysis, 35
2,3-Dehydro-2-deoxy-*N*-acetyl
 neuraminic acid, 150
Design space, 93, 110, 118
Dihydrofolate reductase (DHFR), 14
Disposables, 69, 85
DNA, 123
 microarrays, 231

E

End of production cells (EOPC/EPC), 173
 Epizootic hemorrhagic disease
 virus (EHDV), 169
 Erythropoietin (EPO), 13
 Excess capacity, 185, 199
 Extended cell bank (ECB), 174

F

Factor VII, 129, 151
 Factor VIII, 2, 12, 39, 128, 149
 Factor IX, 12, 129, 151
 Factor X, 129, 151
 Failure mode and effects analysis (FMEA), 96
 Fc-fusion protein, 253
 Fed-batch, 8, 35, 40
 Feeding strategy optimization, 43
 Flow cytometry, 22
 Fluorescence activated cell sorting (FACS), 22
 Forecast, 185
 Fucosidase, 149
 FUT8 transferase, 16

G

β -Galactosidase, 13, 149
 GDP-6-deoxy-D-lyxo-4-hexulose
 reductase, 16
 Gene expression analysis, 234
 Glucose, 38–49, 52, 53, 114, 129, 144, 231
 Glutamine, 15, 42, 44, 54, 85, 133–137
 Glutamine synthetase (GS), 15
 γ -Glutamyl carboxylase, 151
 Glycation, 144
 Glycerol-3-phosphate dehydrogenase
 (GPDH), 46
 Glycoprotein, 13
 Glycosidases, 148
 Glycosylation, 123, 141–144, 187
 Glycosyltransferase, 16

H

Hamster antibody production (HAP), 173
 Heat shock experiments, 230
 HEK293, 5
 β -Hexosaminidase, 149
 Host cell proteins (HCP), 123, 151
 HT-1080, 5
 Human cell lines, 5
 β -Hydroxylation, 151

I

Impellers, 80
 Impurities, 123
 In-process testing, 170
 Initial process parameter risk
 assessments, 98
 Inoculation train, 75
 Integral of viable cell concentration (IVCC), 7
 Interferons, 2, 70, 128, 131, 149, 150, 190
 Internal ribosome entry site (IRES), 23

K

Key process attribute X (KPA-X), 236

L

Lactate dehydrogenase A (LDH-A), 46
 Lactate, 35, 42–52, 85, 104, 114, 231
 metabolism, 35, 42
 Log reduction factor (LRF), 170
 Log reduction value (LRV), 170

M

Macrospargers, 82
 Maillard reaction, 144
 Mammalian cell cultures, 1, 11, 35, 69, 123,
 167, 185, 227
 Mass flow controllers (MFC), 83
 Master cell bank (MCB), 170
 Matrix attachment regions (MARs), 20
 Media components, 123
 Meganucleases, 15
Mesocricetus auratus, 229
 Methionine sulphoximine (MSX), 15
 Methotrexate (MTX), 14
 Microarrays, 231
 Microspargers, 82
 Misfolding, 126
 Mixing, 80
 Monoclonal antibodies, 69, 190
 Mouse antibody production (MAP), 173
 Mouse myeloma cells, 5, 168
 Multiproduct manufacture, 249
 Multivariate data analysis (MVDA), 59
 Murine minute virus (MMV), 168
Mus musculus, 229

N

NS0, 5, 168

O

- Operating space, 110
- Out of specification (OOS) results, 175

P

- Parental cell bank (PCB), 170
- Peptidylglycine alpha-amidating monooxygenase (PAM), 141
- Perfusion, 8, 35, 41, 47, 69, 227, 230
 - cell retention devices, 89
- Phosphorylation, 152
- Polyoma virus, 229
- Post-approval changes, 245
- Post-authorization safety study (PASS), 250
- Preculture, 69
- Pre-master research cell banks (pmRCB), 171
- Principal components analysis (PCA), 59
- Process development, 123
- Process-related impurities, 151
- Product lifecycle management, 245
- Product quality, 123, 153
- Production cell lines, 1
- Proteases, 148
- Proteins, aggregation, 131
 - expression, 11
 - secretion, 136
 - therapeutic, 71
- Proven acceptable ranges (PAR), 179
- Pumps, 83
- Pyroglutamate, 137
- Pyruvate carboxylase (PC), 46
- Pyruvate dehydrogenase kinases (PDHKs), 46

Q

- Quality by design (QbD), 93, 94
- Quality target product profile (QTTP), 95

R

- R&D, productivity, 248
- Raw materials, potential source of viral contamination, 170
 - risk assessment, 100
- Recombinant proteins, 2, 13, 21, 35, 134, 144, 186, 229, 245
- Reovirus (Reo), 169
- Resources, 252
- Retrospective monitoring, 60
- Retroviruses, 152
 - detection, 172–174
- Retrovirus-like particles (RVLP), 168

- Risk assessment, 93

- Risk factors, 251
- RNA, extraction, 231

S

- Safety assurance, 167
- Scale-down, 112, 227
- Scale-up, 46, 69, 93
- Seed train, 69
 - expansion, 72
- Sialidase, 149
- Sialyltransferase, 15
- Single use, 69, 185, 210, 214
- Solenoids, 83
- SP2/0, 5
- Spargers, 81
- Stirred tank, 78, 80, 86
- Sulfation, 152

T

- TALENs, 15
- Technology lifecycle management, 245
- Transcriptome analysis, 229
- Transcriptomics, 227
- Transmissible spongiform encephalopathy (TSE), 169

U

- Unprocessed bulk (UPB), 175

V

- Vesivirus, 169, 175, 177
- Viral clearance, 167
- Viral contamination, 167
- Viral particles, 123
- Viral safety, 167
 - clinical trials, 179
- Virus clearance, downstream purification, 177
- Vitamin K epoxide reductase, 151

W

- WAVE, rocking platform, 78, 80
- Working cell bank (WCB), 171

Z

- Zinc finger endonucleases, 15